Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 6/20 | 0.52 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.47 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALDH3A1 | P30838 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29847207 | 1.00 | MET (0.52) | METCXCL8NOD1RECQLLMNA | |
| SCHEMBL21295075 | 0.82 | MET (0.40) | METCXCL8NOD1RECQLLMNA | |
| SCHEMBL29847060 | 0.82 | MET (0.40) | METCXCL8NOD1RECQLLMNA | |
| SCHEMBL21147693 | 0.80 | MET (0.58) | METCXCL8NOD1RECQLLMNA | |
| SCHEMBL16818826 | 0.78 | NOD1 (0.45) | CXCL8NOD1RECQLLMNAALDH1A1 | |
| SCHEMBL30276218 | 0.78 | CA12 (0.52) | CXCL8NOD1RECQLLMNAALDH1A1 | |
| SCHEMBL369194 | 0.78 | CA12 (0.52) | CXCL8NOD1RECQLLMNAALDH1A1 | |
| SCHEMBL1773227 | 0.78 | CYP2C19 (0.52) | METCXCL8NOD1RECQLLMNA | |
| SCHEMBL16795088 | 0.76 | SRC (0.40) | METCXCL8NOD1RECQLLMNA | |
| SCHEMBL5833331 | 0.74 | RECQL (0.43) | CXCL8NOD1RECQLLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110194770-B | Peptidyl arginine deiminase inhibitors and uses thereof | 药捷安康(南京)科技股份有限公司 | 2022-08-09 | — | — | CN | disclosed |
| EP-3760628-A1 | PEPTIDYLARGININE DEIMINASE INHIBITOR AND USE THEREOF | Nanjing Transthera Biosciences Co., Ltd. (CN) | 2021-01-06 | — | — | EP | disclosed |
| EP-3760628-A1 | PEPTIDYLARGININE DEIMINASE INHIBITOR AND USE THEREOF | Nanjing Transthera Biosciences Co., Ltd. (CN) | 2021-01-06 | — | — | EP | disclosed |
| US-20200407370-A1 | PEPTIDYLARGININE DEIMINASE INHIBITOR AND USE THEREOF | NANJING TRANSTHERA BIOSCIENCES CO., LTD. (CN) | 2020-12-31 | — | — | US | disclosed |
| US-20200407370-A1 | PEPTIDYLARGININE DEIMINASE INHIBITOR AND USE THEREOF | NANJING TRANSTHERA BIOSCIENCES CO., LTD. (CN) | 2020-12-31 | — | — | US | disclosed |
| CN-110194770-A | Peptide acyl arginine deiminase inhibitor and application thereof | 南京药捷安康生物科技有限公司 | 2019-09-03 | — | — | CN | disclosed |
| WO-2019161803-A1 | PEPTIDYLARGININE DEIMINASE INHIBITOR AND USE THEREOF | 南京药捷安康生物科技有限公司 | 2019-08-29 | — | — | WO | disclosed |
| WO-2019161803-A1 | PEPTIDYLARGININE DEIMINASE INHIBITOR AND USE THEREOF | 南京药捷安康生物科技有限公司 | 2019-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200407370-A1 | PEPTIDYLARGININE DEIMINASE INHIBITOR AND USE THEREOF | PADI4, PADI2, PADI1 | MET 3824/4885CXCL8 1642/4885NOD1 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.